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Abstract
Adiponectin (APN), an adipocytokine produced by adipose tissue, exerts pleiotropic actions regulating inflammation,
metabolism and vascular homeostasis. APN levels are inversely correlated with obesity, type-2 diabetes, hypertension and
cardiovascular disease. Although renin angiotensin system (RAS) activation in these interrelated metabolic syndrome
components increases angiotensin II (AngII) levels leading to vascular damage, it is unknown whether APN under these
conditions provides atheroprotection. We investigated whether increasing plasma APN provides atheroprotection in a
hypertensive and accelerated atherosclerosis model. Using adenoviral gene transfer, sustained APN expression increased
plasma levels of total and high-molecular weight APN, leading to a significant elevation of plasma HDL-cholesterol (HDL-C).
Elevated APN levels were strongly atheroprotective, yet had no impact on blood pressure. Notably, gene expression
analyses revealed that APN significantly inhibited the expression of pro-inflammatory and atherogenic genes while it
increased the expression of the anti-inflammatory cytokine, IL-10 and the cholesterol efflux transporters, ABCA1 and ABCG1
in the artery wall. These findings suggest that increasing APN levels may be an effective therapeutic strategy to inhibit
vascular inflammation and accelerated atherosclerosis associated with RAS activation in the metabolic syndrome.
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Introduction
Obesity is closely linked to the metabolic syndrome including
dyslipidemia, insulin resistance and hypertension, which promote
the development of diabetes and atherosclerotic cardiovascular
disease. Adipose tissue is now recognized as an endocrine organ
that produces multiple bioactive mediators, known as adipokines
that play a functional role in the regulation of metabolism,
inflammation and tissue remodeling [1,2]. In obesity-related
disorders, excess visceral fat accumulation leads to adipose
macrophage infiltration and metabolic dysfunction contributing
to low-grade local and systemic inflammation, which contribute to
the pathogenesis of cardiovascular complications [3,4].
APN (also known as apM1, AdipoQ, Acrp30, GBP-28) is an
adipokine that has emerged as an important therapeutic target due
to its pleiotropic actions regulating metabolism, inflammation,
immune response and vascular homeostasis [5,6]. Structurally,
APN contains a collagen-domain at its N-terminus and a globular
domain at the C-terminus with a sequence homology to
complement C1q [7,8,9]. APN circulates at relatively high
concentrations in plasma (3–30 mg/mL) and forms three high-
order oligomeric forms: a high molecular weight form (HMW, 12–
32-mer), a medium molecular weight form (MMW, hexamer) and
a low molecular weight form (LMW, trimer) [9,10,11]. In contrast
to other adipokines, adipose expression and plasma concentrations
of APN are reduced in the metabolic syndrome, diabetes and
cardiovascular disease [6,12,13]. Indeed, clinical studies have
demonstrated that plasma APN levels negatively correlate with
visceral adiposity, hyperlipidemia, and insulin resistance, but
correlate positively with HDL-C levels [14,15]. Furthermore, low
plasma HMW APN levels rather than total APN levels are a
superior biomarker of insulin resistance and metabolic syndrome
[10,11]. Notably, APN mediates its effects through interaction
with specific APN receptors, AdipoR1 and AdipoR2, to activate
signal transduction pathways mediated by AMPK and PPARa in
target tissues [13], [16]. Thus, agents that stimulate the expression
of APN or APN receptor agonists are promising therapeutic
targets for the metabolic syndrome.
The RAS is a key regulator of blood pressure and cardiovas-
cular function [17]. RAS activation in the metabolic syndrome
leads to increased AngII levels, driving arterial wall inflammation,
oxidative stress and atherosclerotic lesion development [18,19,20].
Studies in high-fructose fed rats have shown that RAS activation
reduces plasma APN levels due to increased oxidative stress which
inhibits adipokine production [21,22]. Clinical studies have not
only shown a relationship between plasma APN levels and
hypertension but also that low APN levels are a predictor of
future hypertension [23,24,25]. Furthermore, APN-deficient mice
under high-salt stress develop hypertension that can be amelio-
rated by APN expression. Similarly, APN expression decreases
hypertension in obese and hypertensive KKAy mice [26].
Although RAS inhibition is known to provide cardiovascular
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protection, it produces only modest improvements in vascular
inflammation and the beneficial effects are mostly independent of
blood pressure reduction [17]. Intriguingly, RAS inhibition by
either angiotensin converting enzyme (ACE) inhibitors or angio-
tensin receptor (AT1) blockers was associated with increased
circulating APN levels and improved cardiovascular status
[27,28,29].
APN exerts potent anti-inflammatory and anti-atherogenic
effects in vascular cells [12,30], thus, linking adipose tissue
physiology to vascular function. Available in vitro evidence suggests
that APN protects against AngII and TNFa-induced endothelial
dysfunction and decreases the expression of endothelial adhesion
molecules [31,32,33]. APN also inhibits the expression of
scavenger receptor, SRA1 and upregulates expression of the
cholesterol efflux promoting transporter, ABCA1, in monocyte-
derived macrophages [34]. In spite of these effects in vitro and
in vivo, the atheroprotective role of APN in dietary models of
atherosclerosis has remained unclear. Studies using either the loss-
or gain-of-APN function in mouse models have shown a protective
role for APN against endothelial dysfunction and hypertension
[26,35]. Although short-term adenoviral APN expression inhibited
atherosclerosis [36], subsequent studies by Nawrocki et al. found
that neither APN-deficiency nor APN overexpression affected
atherosclerosis in LDLR2/2 mice fed a low-fat or high-fat diet as
well as in APN-deficient ApoE mice [37]. However, no studies
have assessed the impact of APN in model of metabolic syndrome
with cardiovascular complications, especially vascular inflamma-
tion and hypertension.
In the metabolic syndrome, RAS activation contributes to
vascular damage, inflammation and atherosclerosis. It remains to
be determined whether APN expression under these conditions
provides atheroprotection. Here, we addressed the hypothesis that
increasing plasma APN levels provides therapeutic benefit by
inhibiting AngII-mediated vascular inflammation and atheroscle-
rotic lesion development in a hypertensive and accelerated
atherosclerosis LDLR2/2 model [38]. Using this model, we
demonstrate that APN exerts profound anti-inflammatory and




Male LDLR2/2 mice (3 months of age) from Jackson
Laboratories (Bar Harbor, ME, USA) were randomly divided
into 3 groups (n = 12–16 mice/group) and fed a high-fat (HF) diet
(Research Diets, New Brunswick, NJ, USA, Western diet
D12079B; protein 17 kcal%; carbohydrate 43 kcal%; fat
41 kcal%). Mice were administered either vehicle (PBS), GFP
virus (26108 PFU) or APN virus (26108 PFU) via retro-orbital
injection. One day after injection the mice were infused with
AngII (Calbiochem, Gibbstown, NJ, USA) or PBS through
subcutaneous implantation of osmotic mini-pumps (Alzet, Cuper-
tino, CA, USA) containing AngII (2.5 mg/kg per minute) in PBS
or PBS alone for 4 or 8 weeks. Blood pressures were measured
daily until plateau level was attained and then weekly for the
duration of the study by the tail-cuff method using BP-200 form
Visitech system Inc. (Apex, NC, USA). All animals used in this
study were approved by the Animal Research Committee,
University of California, Los Angeles, CA.
Quantification of Atherosclerosis and
Immunohistochemistry
Mice were euthanized and perfused with 7.5% sucrose in 4%
paraformaldehyde. 1 mM EDTA, pH 7.4. The entire aorta was
dissected out, split longitudinally, pinned flat in a dissociation pan,
and stained with Sudan IV to determine lesion area. Images were
captured by Sony 3-CCD video camera and analyzed using
ImagePro image analyzing software (Media Cybernatic Inc.,
Bethesda, MD, USA). The extent of atherosclerotic lesion
formation is expressed as the percentage of the total aortic surface
area covered by lesions [39]. The total lesion area in Oil Red O-
stained aortic root sections was determined on digitized images
from 3 equally spaced sections per mouse (n = 5 per group).
Immunohistochemical analyses of aortic root sections were
performed as described [40] with antibodies specific for macro-
phages MOMA2 and APN. Collagen in lesions was detected by
using Masson trichrome stain. The macrophage and collagen-
positive areas in stained aortic root sections (5 equally spaced
sections per mouse n= 3–5 per group) were quantified using
Image Pro Plus image analysis and the data are expressed as
percent of total lesion area.
Construction of Recombinant APN Adenovirus
The mouse APN cDNA was inserted in the pAxCAwT plasmid
(TAKARA Biomedical, Shiga, Japan) to generate pAxCAwt-
mouse APN. The resulting plasmid containing APN cDNA was
under the control of CAG promoter (CMW enhancer, chicken b-
actin promoter, and part of an untranslated region of rabbit b-
globin). The virus was expanded by ViraQuest, Inc. (North
Liberty, IA, USA).
Analysis of Gene Expression
Gene expression in whole aortas was measured by quantitative
real-time PCR [38]. For RNA isolation, aortas from mice
prepared as described were perfused with ice-cold PBS and
quickly frozen in liquid nitrogen and stored at 280uC until RNA
extraction. Total RNA from the aortas was isolated using Rneasy
kit and DNase (QIAGEN, Valencia, CA, USA), then reverse
transcribed into cDNA using Taqman Reverse Transcription
Reagent Kit (Applied Biosystems, Foster City, CA, USA).
Quantitative real-time PCR (SYBR green) was performed with
an ABI-PRISM 7500 system (Applied Biosystems) in a total
volume of 20 ml, using a TaqMan PCR Core Reagent Kit
(Applied Biosystems). The reaction profile was 2 min 50uC,
10 min 95uC and 40 cycles of 15 min 95uC and 1 min 60uC
followed by 15 sec 95uC, 1 min 60uC and 15 sec 95uC. Each
sample was analyzed in duplicate and normalized to the value of
GAPDH mRNA expression. The primer sequences for investigat-
ed genes are shown in Table-1.
Western Blot Analyses
For the detection of ApoA1, ApoB and APN in plasma and liver
extracts from mice were resuspended in 40 mL of Laemli buffer
(Bio-Rad) and heated at 95uC for 5 min. The samples were
subjected to 10–20% linear gradient SDS-polyacrylamide gel
electrophoresis and transferred to nitrocellulose membranes. The
presence of ApoA1, ApoB and APN was detected using anti-
mouse ApoA1, ApoB and APN antibodies as primary and
horseradish peroxidase-labeled rabbit anti-muse IgG as secondary
antibody.
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Determination of Plasma Lipid Levels and Metabolic
Factors
Plasma samples from mice were collected after fasting and total
cholesterol, HDL-C, triglycerides and free fatty acids were
analyzed by enzymatic methods (Wako Chemicals USA, Inc.,
Richmond, VA, USA). Blood glucose levels were measured by
one-touch glucose monitoring system (Wako). Serum APN levels
were measured by Adiponectin ELISA kit (Otsuka Pharmaceuti-
cals Inc., Rockville, MD, USA). The distribution of cholesterol in
the lipoprotein subclasses in plasma was determined by Fast
performance liquid chromatography (FPLC) of 200 mL of pooled
plasma samples from each of the experimental groups using a
Superose 6 column (LKB Biotechnology, Uppsala, Sweden). Total
cholesterol content in the lipoprotein fractions was determined
using enzymatic colorimetric assays (see above).
Determination of Plasma APN Oligomeric Form Levels by
Western Blot
To determine the amount of APN in plasma samples of mice
and the oligomeric forms of APN in the serum, 0.1 ml of serum was
loaded onto a 4–12% NuPAGE gel (Invitrogen). The gel for the
APN oligomeric forms was run under non-reducing, non-
denaturing conditions according to previously published method
[10,11]. The gels were blotted onto nitrocellulose with the iBlot
dry blotting system (Invitrogen). APN was visualized using anti-
mouse APN antibody (R&D systems, Minneapolis, MN, USA).
Statistical Analyses
All data were expressed as mean 6 standard deviation.
Statistical significance was determined by 1-way ANOVA, New-
man-Keuls post-test and unpaired Student t-test with GraphPad
Prism software. Experimental groups were compared to the
vehicle group with the Dunnet test. Statistical differences for all
comparisons was set at p,0.05.
Results
Long-term APN Expression Alters the Distribution of APN
Oligomeric Forms in an AngII-induced Hypertensive
Model of Accelerated Atherosclerosis
To investigate the effects of long-term APN expression on
AngII-mediated vascular inflammation and atherosclerosis, we
used hepatic adenoviral gene transfer to achieve chronic elevation
of plasma APN levels in the AngII-induced LDLR2/2 model of
atherosclerosis. At baseline, plasma APN levels were 30.4 mg/mL
in chow diet-fed LDLR2/2 mice. After 8 weeks of high-fat (HF)
feeding, the plasma APN levels were significantly reduced
compared to baseline APN levels (38% reduction)(Figure 1A).
To induce APN expression and increase circulating APN levels,
AngII-infused male LDLR2/2 mice fed HF were intravenously
injected with adenovirus expressing mouse APN (AdAPN) or
control adenovirus expressing green florescent protein (AdGFP).
Determination of plasma APN levels by ELISA after viral injection
revealed peak APN levels at day 7 (17-fold elevation vs GFP). The
APN levels on day 56 after viral injection demonstrated a 10-fold
elevation in AdAPN mice compared those in Ad-GFP mice
(Figure 1A). Consistent with these results, Western blot analysis of
plasma samples at 8 weeks of APN expression showed more than
5-fold increase in APN in AdAPN mice compared with AdGFP
mice (Figure 1B). Next, we determined the effects of AngII
infusion and exogenous APN on adipose APN expression. Analysis
of adipose mRNA levels after 8 weeks of treatment showed that
AngII infusion significantly suppressed APN levels in the adipose
tissue which was unaffected adenoviral expression of APN in the
liver (Figure 1C).
Plasma APN circulates in three major oligomeric forms: HMW,
MMW and LMW forms [10,11] thus we next determined the
effect of adenoviral APN expression on the distribution of APN
oligomeric forms in the AngII-induced model of atherosclerosis. In
plasma obtained after 8 weeks of treatment, measurement of APN
using non-reducing and non-denaturing gel electrophoresis
revealed that APN expression in AdAPN mice significantly
increased the proportion of HMW APN (Figure 2D). Correspond-
ingly, there was a reduction in the proportion of MMW APN in
AdAPN mice compared to AdGFP controls (Figure 1E). A
comparison of APN oligomeric forms between HF/AngII/AdGFP
Table 1. Primer sequences of genes used for quantification of
mRNA levels by real-time PCR.





MCP-1 Forward TTA AAA ACC TGG ATC GGA ACC AA
Reverse GCA TTA GCT TCA GAT TTA CGG GT
CCR2 Forward ATC CAC GGC ATA CTA TCA ACA TC
Reverse CAA GGC TCA CCA TCA TCG TAG
TNF-a Forward CCC TCA CAC TCA GAT CAT CTT CT
Reverse GCT ACG ACG TGG GCT ACA G
CD11c Forward AGA CGT GCC AGT CAG CAT CAA C
Reverse CTA TTC CGA TAG CAT TGG GTG AGT G
IL-6 Forward GGT GCC CTG CCA GTA TTC TC
Reverse GGC TCC CAA CAC AGG ATG A
IL-10 Forward GCT CTT ACT GAC TGG CAT GAG
Reverse CGC AGC TCT AGG AGC ATG TG
IL-12p40 Forward TGG TTT GCC ATC GTT TTG CTG
Reverse ACA GGT GAG GTT CAC TGT TTC
Osteopontin Forward AGC AAG AAA CTC TTC CAA GCA A
Reverse GTG AGA TTC GTC AGA TTC ATC CG
SR-A1 Forward GCA CAA TCT GTG ATG ATC GCT
Reverse CCC AGC ATC TTC TGA ATG TGA A
SR-B1 Forward TTT GGA GTG GTA GTA AAA AGG GC
Reverse TGA CAT CAG GGA CTC AGA GTA G
CD36 Forward AGA AGG CGG TAG ACC AGA C
Reverse GTA GGG GGA TTT CTC CTT GGA
ABCA1 Forward AAA ACC GCA GAC ATC CTT CAG
Reverse CAT ACC GAA ACT CGT TCA CCC
ABCG1 Forward CTT TCC TAC TCT GTA CCC GAG G
Reverse CGG GGC ATT CCA TTG ATA AGG
AT1R Forward AAC AGC TTG GTG GTG ATC GTC
Reverse CAT AGC GGT ATA GAC AGC CCA
AT2R Forward ATG CTT GGG GCA ACT TCA CTA
Reverse GCA GCA AGA GAA GGG CTT CA
ApoAI Forward GGC ACG TAT GGC AGC AAG AT
Reverse CCA AGG AGG AGG ATT CAA ACT G
ApoAII Forward TGG TCG CAC TGC TGG TAA C
Reverse TTT GCC ATA TTC AGT CAT GCT CT
ApoB100 Forward TTG GCA AAC TGC ATA GCA TCC
Reverse TCA AAT TGG GAC TCT CCT TTA GC
PPARa Forward AGA GCC CCA TCT GTC CTC TC
Reverse ACT GGT AGT CTG CAA AAC CAA A
doi:10.1371/journal.pone.0086404.t001
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mice and HF/PBS mice revealed that AngII treatment had no
significant effect on APN distribution (Figure 1E). These results
indicate that more than 30% of plasma APN circulates in the
HMW form in AdAPN mice. Since HMW APN is a known to
improve component of the metabolic syndrome, AdAPN mice are
thus a model for APN therapy.
APN Expression Improves HDL-C Levels and Hepatic
Apolipoprotein Expression without Blood Pressure
Reduction
AngII infusion in LDLR2/2 mice fed high-fat diet for 8 weeks
in Ad-GFP and Ad-APN mice significantly increased their blood
pressure (.40 mmHg. P,0.01) compared to control mice infused
with PBS (Table-2). APN expression had no significant effect on
AngII-induced blood pressure (Table-2). Both body and adipose
tissue weights were significantly reduced in AngII-infused AdGFP
and AdAPN mice compared with control PBS-infused mice
(Table-2). Notably, the reduction of liver weight due to AngII-
infusion after 8 weeks was absent in AdAPN mice (Table-2).
Plasma total cholesterol, triglycerides, fatty acids, and fasting
glucose levels at 8 weeks of treatment showed no significant
differences between AdGFP and AdAPN mice (Table-2).
A number of studies reported a positive correlation between
plasma APN and HDL-C levels. Thus, we determined the impact
of APN expression on plasma lipoproteins by analyzing lipoprotein
profiles, HDL-C and apolipoprotein levels. APN expression
significantly increased plasma HDL-C levels by 28% in AdAPN
mice (Figure 2B). This increase in HDL-C was observed 7-days
after adenoviral APN injection (data not shown). The effect of
APN expression on plasma lipoprotein profiles was examined by
measuring cholesterol distribution in lipoprotein fractions. The
overall, the lipoprotein profile of Ad APN mice indicated higher
HDL-C, while ApoB-containing lipoproteins appeared compara-
ble to AdGFP controls (Figure 2A). To determine whether APN
expression affects apolipoproteins associated with HDL and LDL
Figure 1. Effect of adenoviral APN expression on plasma levels, endogenous adipose tissue APN expression and distribution of
plasma APN oligomeric forms in AngII-infused LDLR2/2 mice. A: Plasma APN levels in AdGFP and AdAPN-injected LDLR2/2 mice, infused
with PBS or AngII and fed high-fat diet for 8 weeks, were measured by ELISA (**p,0.05 baseline vs HF/PBS; *p,0.001 vs HF/AngII/AdAPN, n= 8/
group) and B: by Western blotting. C: APN mRNA levels in white adipose tissue were analyzed QRT-PCR and normalized to GAPDH (*p,0.05 vs HF/
PBS, n = 5/group). D: APN isoform distribution in plasma from HF/PBS, HF/AngII/AdGFP and HF/AngII/AdAPN LDLR2/2 mice was resolved by non-
denaturing Western blot analysis (LMW= low molecular weight, MMW=medium molecular weight, HMW=high molecular weight form). E: Plasma
APN oligomeric forms quantified were expressed as percent of total APN levels (*p,0.01, HF/AngII/AdGFP vs. HF/AngII/AdAPN, n = 3/group).
doi:10.1371/journal.pone.0086404.g001
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in the plasma, we performed Western blot analyses of plasma
samples obtained at 8 weeks of AngII-infusion and APN
treatment. The results revealed higher plasma ApoA1 levels in
AdAPN mice compared with those in AdGFP mice (Figure 2C).
However, no apparent changes in plasma ApoB100 and ApoB48
protein levels were detected (Figure 2C). These data suggest that
APN expression increases plasma ApoA1, the major component of
HDL, which is critical for HDL-biogenesis and reverse cholesterol
transport.
Adiponectin Increases Hepatic Adiponectin Receptor and
Apolipoprotein Gene Expression
Since the liver is the central organ controlling lipid metabolism
and reverse cholesterol transport [41,42], we investigated the
impact of APN on hepatic expression of APN receptors and genes
regulating HDL and lipid homeostasis. Analysis of APN receptors
in the liver revealed that AngII significantly suppressed the
expression of AdipoR1 and AdipoR2 (p,0.05, HF/PBS vs HF/
AngII/AdGFP) (Figure 3A). Interestingly, APN not only inhibited
the suppressive effect of AngII, but also significantly enhanced the
hepatic expression of AdipoR1 and AdipoR2 beyond the levels
observed in HF/PBS mice (Figure 3A). Since APN signaling via
AdipoR2 activates peroxisome proliferator-activated receptor
alpha (PPARa) [13], a key gene in HDL and triglyceride
metabolism, we measured PPARa mRNA expression in the liver.
Consistent with AdipoR2 suppression, hepatic PPARa mRNA
levels were also reduced in HF/AngII/AdGFP mice compared to
those in HF/PBS mice (Figure 3A). Notably, APN mitigated the
AngII suppression of hepatic PPARa expression (Figure 3A). We
also sought evidence for APN regulation of apolipoprotein genes
involved in lipid metabolism in vivo by measuring apolipoprotein,
Figure 2. Effect of elevated adiponectin levels on plasma lipoprotein profile, HDL-cholesterol and apolipoprotein levels. A: Plasma
lipoprotein profiles of HF/PBS, HF/AngII/AdGFP and HF/AngII/AdAPN pooled samples were determined by fast performance liquid chromatography.
B: Plasma HDL-C levels determined by enzymatic method (*p,0.001 HF/AngII/AdGFP vs HF/AngII/AdAPN, n = 8/group ). (C) Western blot analysis of
plasma apolipoproteins A1, B100 and B48 levels in pooled samples from HF/PBS, HF/AngII/AdGFP and HF/AngII/AdAPN after 8 weeks of adiponectin
expression.
doi:10.1371/journal.pone.0086404.g002
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ApoA1, ApoB mRNA and protein levels. Although hepatic ApoA1
mRNA levels revealed no change after APN expression
(Figure 3A), we found a substantial increase in hepatic ApoA1
protein expression by Western blot analysis (Figure 3B). Further-
more, APN significantly suppressed hepatic ApoB mRNA and
ApoB100 protein levels and modestly reduced ApoB48 protein
levels in AdAPN mice compared to AdGFP controls (Figure 3A
and B).
In hepatocytes, ABCA1 plays an important role in HDL
formation. Available in vitro studies indicate that APN increases the
expression of ABCA1 but not ABCG1 in hepatocytes [43]. In this
study, we provide in vivo evidence that APN expression signifi-
cantly increased ABCA1 while it suppressed ABCG1 in the liver
(AdGFP vs AdAPN, p,0.05) (Figure 3A). Furthermore, we
observed increased hepatic PPARa in AdAPN mice, which is a
downstream target of APN that may contribute to ABCA1
induction. These in vivo results indicate that APN may contribute
to HDL elevation in part by increasing the expression of ABCA1
in the liver.
Adiponectin Expression Provides Atheroprotection in a
Hypertensive Model of Accelerated Atherosclerosis
without Reducing Blood Pressure
We investigated whether APN provides atheroprotection
against AngII-mediated inflammation and atherosclerosis using a
hypertensive and accelerated atherosclerosis LDLR2/2 model.
Previous studies in our laboratory have extensively characterized
this model for a number of anti-atherogenic interventions relevant
to cardiovascular complications of the metabolic syndrome in
which RAS activation and AngII elevation play a pathogenic role
[38,44]. Male LDLR2/2 mice fed high-fat diet and infused with
AngII were injected with either AdGFP or AdAPN. To determine
whether APN provides atheroprotection against AngII-accelerated
atherosclerosis, aortas were prepared from separate cohorts of
AdGFP and AdAPN mice (n = 12–16 mice/group) after 4 or 8
weeks of treatment. The extent of atherosclerotic lesion develop-
ment in entire aortas was quantified by en face analysis [39]. Sudan-
IV stained en face aortic preparations after 4 and 8 weeks revealed
extensive atherosclerotic lesion development throughout the aortic
surface in AdGFP mice which was obviously reduced in the
AdAPN mice (Figure 4A). En face quantification of atherosclerosis
in the entire aortas after 8 weeks of treatment demonstrated that
APN expression significantly inhibited AngII-accelerated athero-
sclerosis (48% reduction, p,0.01). (Figure 4B). In addition,
quantification of lesion size in aortic root sections revealed a
significant reduction of lesion size in AdAPN mice compared to
that in AdGFP mice (45% reduction, p,0.05) (Figure 4C). These
results provide important evidence that APN expression markedly
inhibited AngII-mediated atherosclerotic lesion development in a
hypertensive and accelerated atherosclerosis model.
Adiponectin Expression Alters Atherosclerotic Lesion
Composition
We examined the effect of APN expression on atherosclerotic
lesion composition in mice after 8 weeks of treatment. Immuno-
staining of aortic root lesions with macrophage-specific antibody,
MOMA2 showed a significant reduction in macrophage-positive
aortic lesion area in AdAPN mice (48.3610.3) compared with
those in AdGFP (26.568.7) (45% reduction, p,0.05) (Figure 4C,
MOMA2). Trichrome staining of aortic root lesions to detect
collagen revealed significantly more collagen-positive (blue)
staining, especially in the intimal layer of aortic lesions consistent
with a more stable lesion phenotype in AdAPN mice
(49.164.0)than in AdGFP mice (56.063.0) (12.3% increase,
p,0.05) (Figure 4C, trichrome). We also examined whether
APN expression contributes to increased APN localization in
aortic lesions. Aortic root sections stained with anti-APN antibody
revealed qualitatively strong APN-positive staining in lesions of
AdAPN mice whereas only weak APN staining was detected in
AdGFP lesions (Figure 4C, adiponectin).
Adiponectin Inhibits Macrophage Recruitment and AngII-
mediated Inflammation in the Artery Wall
AngII is a strong inducer of macrophage recruitment, foam cell
formation and inflammatory gene expression in the artery wall
[38,44]. To characterize APN-regulation of vascular inflammatory
gene expression in vivo, we performed quantitative RT-PCR to
determine the gene expression profile of aortas from AngII-infused
mice. As we have shown in previous studies, AngII markedly
increased the aortic expression of the CD68 macrophage marker in
AdGFP mice, and interestingly, consistent with immunohistochem-
istry results, APN expression significantly inhibited CD68 expres-
sion (50% reduction) (AdGFP vs AdAPN, p,0.001). Similarly, a
dendritic cell marker, CD11C, also increased significantly in aortas
after AngII-infusion, yet APN expression did not affect CD11C
levels in the artery wall (Figure 5). Analysis of AngII receptors in the
aorta revealed that AngII increased AT1R while it suppressed
AT2R expression (Figure 5). Interestingly, APN expression
Table 2. Characteristics of high-fat (HF)-fed LDLR2/2 mice infused with AngII or PBS expressing AdGFP or AdAPN.
HF/PBS (n =12) HF/AngII/AdGFP (n =16)
HF/AngII/AdAPN
(n=16)
Initial BP (mm Hg) 118.5611.0 116.469.4 117.767.6
Final BP (mm Hg) 118.0610.5 171.8615.0* 167.0617.0*
Body weight (g) 32.362.8 21.267.8* 23.561.3*
Liver weight (g) 1.3360.2 0.8760.3** 1.2960.3
Adipose tissue weight (g) 1.3460.5 0.3660.14 0.3160.1
Total cholesterol (mg/dL) 837.56185.2 825.1669.7 875.76206.1
Triglycerides (mg/dL) 48.0617.0 162.0636.6 153.0628.9
Fatty acids (mg/dL) 42.665.7 47.262.9 49.266.4
Glucose (mg/dL) 396.9651.1 288.7653.4 320.9641.0
*p,0.05 vs HF/PBS, **p,0.05 vs HF/AngII/AdAPN, BP =blood pressure.
doi:10.1371/journal.pone.0086404.t002
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counteracted AngII effects on AngII receptor expression by
suppressing AT1R while enhancing AT2R expression in the artery
wall (Figure 5). These results indicate that APN modulates aortic
AngII receptor expression to inhibit AngII-mediated inflammation
and vascular damage. Importantly, AngII markedly increased aortic
expression of inflammatory genes including TNF-a, MCP-1, IL-6,
IL-12, ICAM-1, CCR2 and osteopontin in HF/AngII/AdAPN
mice compared to HF/PBS mice (Figure 5). APN significantly
suppressed the expression of all of these AngII-induced inflamma-
tory genes in the artery wall (Figure 5). In case of the anti-
inflammatory cytokine, IL-10, we found that AngII substantially
suppressed its expression whereas APN expression significantly
increased IL-10 in the artery wall (Figure 5). Taken together, these
data demonstrate that APN potently inhibits AngII-induced
inflammation and induces anti-inflammatory factors in the artery
wall.
Adiponectin Expression Inhibits Expression of Scavenger
Receptors and Increases Cholesterol Efflux Transporters
in the Artery Wall
AngII is a strong inducer of foam cell formation and suppresses
the expression of the cholesterol efflux transporter ABCA1,
decreasing macrophage cholesterol efflux and accelerating ath-
erosclerotic lesion development [44]. Since cholesterol homeostasis
is critical in atherosclerosis, we examined the expression of both
scavenger receptors and cholesterol efflux promoting ABC
transporters in the artery wall. Importantly, aortic expression of
cholesterol uptake genes (SR-A1, SR-B1 and CD36) was
substantially increased in HF/AngII/AdGFP mice compared with
control HF/PBS mice (Figure 6). Interestingly, APN expression
significantly suppressed the aortic mRNA levels of SR-A1, SR-B1
and CD36 (Figure 6). These data indicate that APN inhibits
AngII-induced scavenger receptor expression to prevent aortic
cholesterol deposition and foam cell formation. On the other
hand, analysis of aortas from HF/AngII/AdAPN 8-week treated
mice revealed a significant increase in the expression of ABCA1
and ABCG1 compared to HF/AngII/GFP mice despite a
significant reduction in lesion macrophage content (Figure 6).
These results provide important evidence that APN limits
cholesterol deposition and promotes cholesterol efflux from the
artery wall thereby decreasing foam cell formation and athero-
sclerosis.
Figure 3. Adiponectin regulates hepatic adiponectin receptor and metabolic gene expression. A: RNA isolated from liver samples were
analyzed for adiponectin receptor and metabolic target genes by QRT-PCR and the expression was normalized to GAPDH (*p,0.05 vs. HF, **p,0.05
vs HF/Ang/AdGFP, ANOVA, Newman-Keuls, n = 5/group). B: Western blot analyses of hepatic expression of apolipoproteins, ApoA1, ApoB100 and
ApoB48. Representative Western blots were shown from the analyses performed using protein extracts derived from livers of AdGFP and AdAPN mice.
doi:10.1371/journal.pone.0086404.g003
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Discussion
The pathogenesis of atherosclerosis involves increased vascular
inflammation and metabolic dysregulation. Available evidence
strongly supports a role for APN as a potent modulator of both
inflammation and cholesterol metabolism and thereby as an
emerging therapeutic target for atheroprotection [6,12,30].
However, prior studies on the effects of APN in preclinical models
of atherosclerosis are limited and have produced diverse results
[36,37]. Thus, we addressed the hypothesis that elevation of
plasma APN levels inhibits AngII-mediated vascular inflammation
and protects against metabolic syndrome-associated atherosclero-
sis. Using a well-established, AngII-infused hyperlipidemic
LDLR2/2 mouse, we demonstrated that APN expression provides
strong atheroprotection without blood pressure reduction. Ade-
noviral APN expression increased plasma APN levels higher than
GFP-vector and PBS-injected mice for up to 8 weeks as in previous
reports using second/third generation adenoviral vectors express-
ing plasma apolipoproteins in atherosclerosis intervention studies
[45,46]. APN expression increased circulating HMW APN levels
leading to elevated plasma HDL and ApoA1 levels as well as
improved metabolic gene expression profiles in the liver.
Importantly, we demonstrated that increasing plasma APN levels
modulate AngII receptor expression and inhibit AngII-mediated
inflammatory and atherogenic gene expression in the artery wall
(Figure 7).
Previously we have shown that AngII profoundly increases
vascular inflammation and atherosclerosis in high-fat fed LDLR2/2
mice [38]. Here, we showed that AngII infusion for 8 weeks
significantly suppressed endogenous APN expression in the white
adipose tissue. Adenoviral APN expression had no effect on the
AngII-induced suppression of adipose APN expression. Important-
ly, in the AngII-infused mice, adenoviral APN expression resulted in
a substantial increase in the plasma levels of both total and HMW
APN. Several studies have shown that HMW APN is a better
biomarker than total APN and is also more active against insulin
Figure 4. APN expression inhibits AngII-accelerated atherosclerosis and affects atherosclerotic lesion composition. A: Representative
Sudan IV staining of en face aortic preparations showing aortic atherosclerotic lesions (Red) after 4 and 8 weeks of APN expression in HF/AngII/AdGFP
and HF/AngII/AdAPN mice. B: En face quantification of atherosclerotic lesion areas in the aortas of HF/Ang II/AdGFP and HF/Ang II/AdAPN mice after
8 weeks of APN expression (*p,0.01, HF/AngII/AdGFP vs HF/AngII/AdAPN, n = 12–16/group). C: Atherosclerotic lesions in the aortic root,
representative aortic sections from HF/PBS, HF/AngII/AdGFP and HF/Ang II/AdAPN groups and quantification of aortic root lesion area (*p,0.05, HF/
AngII/AdGFP vs HF/AngII/AdAPN, n = 5–7/group). D. Representative aortic root sections stained for lipid (Oil Red O), macrophages (red) using MOMA2
antibody, Masson trichrome staining of lesions for collagen content (blue) and immunolocalization of APN in atherosclerotic lesions (brown) of HF/
AngII/AdGFP and HF/AngII/AdAPN mice (Magnification 200 X).
doi:10.1371/journal.pone.0086404.g004
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resistance and metabolic syndrome [10,47]. A number of clinical
studies reported a direct and positive correlation between plasma
HMW APN and HDL-C levels [14,15]. Consistent with these data,
in our study the elevation of APN as well as HMW APN also led to
increased plasma HDL-C levels in our hypertensive and hyperlip-
idemic model of atherosclerosis.
The liver is the major organ controlling lipid metabolism, HDL
biogenesis and reverse cholesterol transport [41,42]. We demon-
strated that APN induces the hepatic expression of APN receptors
and genes regulating HDL and lipid homeostasis. Previous in vitro
studies reported that APN increases ApoA1 and ABCA1
expression in hepatocytes contributing to HDL formation [43].
Furthermore, both ABCA1 and ApoA1 expression in the liver are
reduced in APN-deficient mice [48]. Our studies provided in vivo
evidence that APN expression increased ApoA1 protein levels in
the liver and plasma, accompanied by HDL-C elevation. Recent
evidence suggests that hepatic ABCA1 expression is a major
regulator of plasma HDL-C levels contributing up to 80% to total
plasma HDL-C levels [49]. In the current study, we found that
APN expression significantly increased ABCA1 mRNA levels in
the liver. In the context of hepatic HDL metabolism, PPARa, a
nuclear hormone receptor, plays a key role in the regulation of
HDL and triglyceride metabolism. In this study, APN prevented
AngII-mediated downregulation of the APN receptors, AdipoR1
and AdipoR2 in the liver. APN signaling through AdioR2 has
been shown to activate PPARa [13,16]. Consistent with the APN
induction of AdipoR2 in the liver, we also showed that APN
increased expression of PPARa in AngII-infused mice. Although
lipoprotein profiles of mice expressing APN revealed only modest
changes in cholesterol within ApoB-containing lipoproteins, we
found a suppression of hepatic ApoB100. Short-term adenoviral
APN expression has been previously reported to reduce plasma
triglyceride levels and hepatic ApoB mRNA levels [50]. In
addition, in vitro studies with human hepatocytes showed that
HMW APN reduced ApoB secretion [51]. Our data demonstrated
that APN altered hepatic gene expression, increasing plasma
HDL-C and ApoA1 levels while reducing the expression of
ApoB100. Importantly, these favorable changes in gene expression
profile together with an elevation of HDL-C can contribute to
atheroprotection by APN. In contrast, AngII induced the
expression of ABCG1, which has been reported to be pro-
atherogenic [52], while APN significantly reduced its expression.
Thus, our results suggest that APN exerts several beneficial actions
in the liver that can contribute to atheroprotection.
A number of clinical and preclinical studies have demonstrated
that elevated plasma APN levels are associated with a low-
incidence of cardiovascular disease [12]. Deficiency of APN in
ApoE2/2 mice promotes atherosclerosis and T-lymphocyte
accumulation in the atherosclerotic lesions [36,53]. Replenishment
of APN by adenoviral expression in these mice attenuated
atherosclerotic lesion formation [36]. In contrast, other studies
have reported that neither genetic overexpression nor APN
Figure 5. Adiponectin inhibits aortic macrophage infiltration and inflammatory gene expression and increases anti-inflammatory
cytokine IL-10 expression. RNA samples from derived from aorta were analyzed for CD68, CD11c, AT-1 receptor, AT-2 receptor, MCP-1, CCR2,
TNFa, IL-10, IL-12, IL-6, ICAM-1, osteopontin, gene expression by QRT-PCR and normalized to GAPDH expression. (*p,0.05 vs HF, **p,0.05 vs HF/
AngII/AdGFP, ANOVA, Newman-Keuls, n = 5–7/group).
doi:10.1371/journal.pone.0086404.g005
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knockout had any significant effect on atherosclerosis in low-fat or
high-fat fed LDLR2/2 mice or ApoE2/2 mice [37]. The reasons
for the differential APN effects observed in previous studies
remains unclear. It is possible that differing APN expression levels,
metabolic and inflammatory factors in previous dietary/genetic
models vs AngII-infused hypertensive model may have contributed
to the divergent outcomes. Here, in the hypertensive, hyperlipid-
emic LDLR2/2 mouse model of accelerated atherosclerosis, APN
expression effectively suppressed macrophage recruitment and
vascular inflammation, contributing to a substantial inhibition of
AngII-accelerated atherosclerosis. It is noteworthy that APN
expression did not affect blood pressure, suggesting that APN
exerts direct anti-inflammatory and anti-atherogenic actions on
the vascular wall independent of blood pressure reduction.
There is evidence suggesting that circulating APN enters the
arterial wall and binds to collagens in the sub-endothelial space of
damaged arteries [54]. In this study, immunohistochemical
analysis not only demonstrated the presence of APN in aortic
lesions of AngII-infused mice but also indicated that the APN
localization in lesions was markedly enhanced in APN expressing
mice. AngII-infusion induces endothelial dysfunction due to
enhanced macrophage recruitment, inflammation and oxidative
stress causing vascular damage [17,18,19]. This study showed that
elevation of APN levels significantly inhibited macrophage
recruitment and inflammation in the artery wall.
APN signaling pathways downstream of AdipoR1 and AdipoR2
include activation of AMPK and PPARa leading to transrepres-
sion of NF-kB and repression of inflammatory gene expression
[55,56,57,58,59,60]. In addition, APN mediated ceramide signal-
ing through depletion of ceramide, independently of AMPK and
PPARa, can also contribute to anti-inflammatory effects [61]. We
demonstrated that elevation of APN levels suppressed aortic
expression of key inflammatory genes (TNF-a, IL-6, IL-12) in a
hypertensive, pro-inflammatory and hyperlipidemic model of
atherosclerosis [38]. Furthermore, we have shown a significant
inhibition of MCP-1 and its receptor CCR2, the chemokine
pathway induced by AngII that contributes to macrophage
recruitment and acceleration of atherosclerosis. Previous studies
reported APN suppression of nuclear factor kB (NFkB)-inducible
genes [36]. The AngII actions contributing to inflammation and
vascular damage are mediated by the angiotensin II type-1
receptor (AT1R) expressed on all vascular cells. Here, we showed
that APN expression inhibited AngII-induced expression of AT1R
in the artery wall. In contrast, AngII suppressed the aortic
expression of angiotensin II type-2 receptor (AT2R), which
antagonizes AngII signaling and contributes to ant-inflammatory
effects [62]. Interestingly, APN expression increased the aortic
expression of AT2R. These findings indicate that APN regulates
the expression of AngII receptors which can potentially modulate
vascular actions of AngII in the artery wall.
Figure 6. Adiponectin expression inhibits scavenger receptor gene expression and increases cholesterol efflux receptors in the
artery wall. (A) RNA isolated from aorta samples were analyzed for scavenger receptors SR-A1, SR-B1 and CD36 and (B) cholestrol efflux receptors,
ABCA1 and ABCG1 expression by QRT-PCR and normalized to GAPDH expression (*p,0.05 vs HF, **p,0.05 vs HF/AngII/AdGFP Newman-Keuls, n = 5–
7/group).
doi:10.1371/journal.pone.0086404.g006
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Clearly, results from this study support the beneficial role of
APN in the suppression of RAS-mediated vascular inflammation
and macrophage accumulation leading to atheroprotection. In
addition, we also demonstrated that APN increased the expression
of the anti-inflammatory cytokine, IL-10 in the artery wall. Recent
evidence implicated APN as an important regulator of macro-
phage polarization. Consistent with its anti-inflammatory proper-
ties, APN has been shown to promote alternative (M2) activation
of macrophages [63], whereas pro-inflammatory conditions lead to
the classical (M1) activation. Interestingly, in AngII-infused mice
we have shown that APN inhibited aortic IL-12 and increased IL-
10, markers of M1 and M2, respectively. This suggests the
possibility that APN may affect macrophage properties, including
their polarization, in atherosclerotic lesions.
Previous studies have shown that AngII promotes macrophage
foam cell formation, which is critical in the pathogenesis of
atherosclerosis [44]. Foam cell formation is regulated by the net
balance between cholesterol influx, mediated by the scavenger
receptors, and cholesterol efflux, facilitated by the ATP-binding
cassette transporters [41]. Furthermore, AngII induces scavenger
receptors, CD36 and SR-A1 in macrophages promoting the
uptake of modified lipoproteins and cholesterol accumulation. It
has been reported that adenoviral APN expression for 2 weeks
reduced the expression of scavenger receptor A1 (SR-A1) but had
no effect on CD36 in the aorta in ApoE2/2 mice [36]. In this
study, adenoviral expression of APN for 8 weeks in AngII-
accelerated LDLR2/2 atherosclerotic mice significantly reduced
the aortic expression of SR-A1, CD36 and SR-B1. Thus, APN
suppresses scavenger receptor expression to reduce macrophage
uptake of modified lipoproteins and foam cell development in
AngII accelerated atherosclerosis. As shown previously, in
hypertensive, hyperlipidemic LDLR2/2 mice, ABCA1 and
ABCG1 are predominantly expressed by macrophages in the
artery wall [44]. Our data indicate that APN expression
substantially increases the expression of cholesterol efflux trans-
porters, ABCA1 and ABCG1 in the artery wall. APN-mediated
activation of PPARa induces LXR target genes, ABCA1 and
ABCG1 [55]. Thus, APN-mediated increase in the artery wall
expression of these efflux receptors suggests that elevated APN
levels effectively promote reverse cholesterol transport. Taken
together, these results suggest that APN inhibits macrophage foam
cell development by suppressing scavenger receptors and increas-
ing efflux transporters to inhibit AngII-accelerated atherosclerosis.
This study provides important evidence that APN expression
exerts profound anti-inflammatory, metabolic and anti-atherogen-
ic actions both in the liver and the artery wall to effectively inhibit
AngII-mediated vascular inflammation and accelerated athero-
sclerosis (Figure 7). Remarkably, the atheroprotective actions of
APN are independent of blood pressure reduction. These studies
strongly support that concept that increasing plasma APN levels
may be an effective therapeutic strategy to inhibit increased
vascular inflammation and accelerated atherosclerosis, especially
relevant to cardiovascular complications triggered by RAS
activation in the metabolic syndrome.
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